Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12
This study has been completed.
Sponsors and Collaborators: National Institute on Drug Abuse (NIDA)
University of Vermont
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00000230
  Purpose

The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with naltrexone.


Condition Intervention Phase
Opioid-Related Disorders
Drug: Buprenorphine
Phase II

Drug Information available for: Buprenorphine Buprenorphine hydrochloride
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment
Official Title: Buprenorphine Detoxification With Two Types of Treatment. BBD III

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Drug use
  • Retention
  • Weeks abstinent
  • Weeks continuous abstinence
  • Overall treatment outcome

Estimated Enrollment: 0
Study Start Date: January 1995
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000230

Locations
United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401
Sponsors and Collaborators
University of Vermont
Investigators
Principal Investigator: Warren Bickel, Ph.D. University of Vermont
  More Information

Study ID Numbers: NIDA-06969-12, R01-06969-12
Study First Received: September 20, 1999
Last Updated: August 16, 2005
ClinicalTrials.gov Identifier: NCT00000230  
Health Authority: United States: Federal Government

Study placed in the following topic categories:
Buprenorphine
Mental Disorders
Substance-Related Disorders
Disorders of Environmental Origin
Opioid-Related Disorders

Additional relevant MeSH terms:
Sensory System Agents
Therapeutic Uses
Narcotic Antagonists
Physiological Effects of Drugs
Central Nervous System Depressants
Narcotics
Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents
Pharmacologic Actions
Analgesics, Opioid

ClinicalTrials.gov processed this record on January 15, 2009